Tolerogenic dendritic cells: Role and therapeutic implications in systemic lupus erythematosus

International Journal of Rheumatic Diseases

Volumn 18, Issue 2, 2015, Pages 250-259

  Mok, Mo Yin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Disease aetiology and pathogenesis animal models; Disease aetiology and pathogenesis human; Innate immunity; Systemic lupus erythematous

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; AUTOANTIGEN; COLECALCIFEROL; CURCUMIN; CYCLOSPORIN; DEXAMETHASONE; GLUCOSAMINE; HLA G ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL THERAPY; CLONAL ANERGY; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NONHUMAN; PATHOGENESIS; PLASTICITY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; TOLEROGENIC DENDRITIC CELL; ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; KNOCKOUT MOUSE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; ROLE PLAYING; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK ASSESSMENT; ROLE; TREATMENT OUTCOME;

EID: 84927910209     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12532     Document Type: Article

References (79)

1. Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30, 1-22.
2. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449, 419-26.
3. Mok MY (2006) Profile of lupus autoantibody found in Asia. APLAR J Rheumatol 4, 331-5.
4. Mok MY, Li WL (2010) Do Asian patients have worse lupus? Lupus 19, 1384-90.
5. Mok MY (2010) The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 13, 3-11.
6. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20, 197-216.
7. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5, 987-95.
8. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6, 823-35.
9. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392, 245-52.
10. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1, 135-45.
11. Huppa JB, Davis MM (2003) T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 3, 973-83.
12. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H (2013) Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 4, 82.
13. Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40, 1830-5.
14. Vieira PL, Christensen JR, Minaee S et al. (2004) IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+ CD25+ regulatory T cells. J Immunol 172, 5986-93.
15. Chabaud M, Durand JM, Buchs N et al. (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42, 963-70.
16. Mok MY, Wu HJ, Lo Y, Lau CS (2010) The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 37, 2046-52.
17. Steinman RM, Nussenzweig MC (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99, 351-8.
18. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-8.
19. Hawiger D, Inaba K, Dorsett Y et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194, 769-79.
20. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192, 1213-22.
21. Lu L, Thomson AW (2002) Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 73, S19-22.
22. Schreibelt G, Tel J, Sliepen KH et al. (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59, 1573-82.
23. Birnberg T, Bar-On L, Sapoznikov A et al. (2008) Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity 29, 986-97.
24. Ohnmacht C, Pullner A, King SB et al. (2009) Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 206, 549-59.
25. Collins CB, Aherne CM, McNamee EN et al. (2012) Flt3 ligand expands CD103(+) dendritic cells and FoxP3(+) T regulatory cells, and attenuates Crohn's-like murine ileitis. Gut 61, 1154-62.
26. Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A (2009) Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood 113, 6277-87.
27. Nakou M, Knowlton N, Frank MB et al. (2008) Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum 58, 3541-9.
28. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48, 2888-97.
29. Jin O, Sun LY, Zhou KX et al. (2005) Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin Rheumatol 24, 107-10.
30. Kushwah R, Hu J (2010) Dendritic cell apoptosis: regulation of tolerance versus immunity. J Immunol 185, 795-802.
31. Ma L, Chan KW, Trendell-Smith NJ et al. (2005) Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol 35, 3364-75.
32. Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ (2010) Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 33, 967-78.
33. Kadowaki N, Ho S, Antonenko S et al. (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194, 863-9.
34. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN (2007) TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13, 543-51.
35. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-28.
36. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540-3.
37. Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F (2005) The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 1051, 421-32.
38. Obermoser G, Pascual V (2010) The interferon-alpha signature of systemic lupus erythematosus. Lupus 19, 1012-9.
39. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225-34.
40. Morelli AE, Thomson AW (2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7, 610-21.
41. Llanos C, Mackern-Oberti JP, Vega F, Jacobelli SH, Kalergis AM (2013) Tolerogenic dendritic cells as a therapy for treating lupus. Clin Immunol 148, 237-45.
42. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23, 975-1028.
43. Voigtlander C, Rossner S, Cierpka E et al. (2006) Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 29, 407-15.
44. Lim DS, Kang MS, Jeong JA, Bae YS (2009) Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol 39, 1334-43.
45. Morelli AE, Thomson AW (2003) Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 196, 125-46.
46. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW (2007) Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178, 7018-31.
47. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L (2001) Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167, 1945-53.
48. Popov A, Schultze JL (2008) IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med (Berl) 86, 145-60.
49. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y (2006) Crystal structure of human indoleamine 2, 3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 103, 2611-6.
50. Terness P, Bauer TM, Rose L et al. (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196, 447-57.
51. Chung DJ, Rossi M, Romano E et al. (2009) Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114, 555-63.
52. Tanaka K, Albin MJ, Yuan X et al. (2007) PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 179, 5204-10.
53. Chauveau C, Remy S, Royer PJ et al. (2005) Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 106, 1694-702.
54. Hill M, Thebault P, Segovia M et al. (2011) Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3. Am J Transplant 11, 2036-45.
55. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Cutting edge: human CD4+ CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172, 4676-80.
56. Kryczek I, Wei S, Zou L et al. (2006) Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177, 40-4.
57. Min WP, Zhou D, Ichim TE et al. (2003) Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 170, 1304-12.
58. Stoop JN, Robinson JH, Hilkens CM (2011) Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis 70, 1526-33.
59. Sarkar S, Fox DA (2005) Dendritic cells in rheumatoid arthritis. Front Biosci 10, 656-65.
60. Page G, Lebecque S, Miossec P (2002) Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 168, 5333-41.
61. Thomas R, Davis LS, Lipsky PE (1994) Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol 152, 2613-23.
62. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM (2010) Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 62, 3656-65.
63. Zandman-Goddard G, Pierangeli SS, Gertel S, Blank M (2014) Tolerogenic dendritic cells specific for beta-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. J Autoimmun 54, 72-80.
64. Kalantari T, Karimi MH, Ciric B, Yan Y, Rostami A, Kamali-Sarvestani E (2014) Tolerogenic dendritic cells produced by lentiviral-mediated CD40- and interleukin-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing T helper type 17 cells. Clin Exp Immunol 176, 180-9.
65. Cong Y, Wang L, Konrad A, Schoeb T, Elson CO (2009) Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur J Immunol 39, 3134-46.
66. Segovia-Gamboa N, Rodriguez-Arellano ME, Rangel-Cruz R et al. (2014) Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients. Clin Immunol 154, 72-83.
67. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M (2011) Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34, 2026-32.
68. Thomas R, Street S, Ramnoruth N (2011) Safety and preliminary evidence of efficacy in as phase I clinical trial of autologous tolerising dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann Rheum Dis 70, 169.
69. Hilkens CM, Isaacs JD (2013) Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol 172, 148-57.
70. Berkun Y, Verbovetski I, Ben-Ami A et al. (2008) Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus. Eur J Immunol 38, 2896-904.
71. Wu HJ, Lo Y, Luk D, Lau C, Lu L, Mok MY (2015) Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. Clin Immunol 156, 43-57.
72. Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162, 5775-83.
73. Moreau A, Varey E, Beriou G et al. (2012) Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials. Front Immunol 3, 218.
74. Kang HK, Liu M, Datta SK (2007) Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 178, 7849-58.
75. Morelli AE, Thomson AW (2014) Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells. Curr Opin Organ Transplant 19, 348-56.
76. Divito SJ, Wang Z, Shufesky WJ et al. (2010) Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood 116, 2694-705.
77. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196, 1627-38.
78. Li X, Li JJ, Yang JY et al. (2012) Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model. PLoS One 7, e44045.
79. Canavan JB, Afzali B, Scotta C et al. (2012) A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 119, e57-66.